A Non-interventional Trial With Avastin as Front-line Treatment for Ovarian Cancer
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Female
Peritoneal Neoplasms, Ovarian Cancer
Female
Peritoneal Neoplasms, Ovarian Cancer
Trial Information
A Non-interventional Trial With Avastin as Front-line Treatment for Ovarian Cancer
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Patients with newly diagnosed advanced epithelial ovarian cancer (EOC), fallopian
tube carcinoma (FTC) or primary peritoneal carcinomas (PPC) with indication for
first-line carboplatin/paclitaxel chemotherapy in combination with Avastin
Exclusion Criteria:
- Contraindications for Avastin according to the Summary of Product Characteristics
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Clinical/demographic patient characteristics at initiation of treatment
Outcome Time Frame:
approximately 4 years
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
Austria: Bundesamt für Sicherheit im Gesundheitswesen (BASG)
Study ID:
ML28355
NCT ID:
NCT01788995
Start Date:
October 2012
Completion Date:
September 2016
Related Keywords:
- Peritoneal Neoplasms, Ovarian Cancer
- Neoplasms
- Ovarian Neoplasms
- Peritoneal Neoplasms
Name | Location |
|---|
